

For COVID-19 technologies, which of these areas would benefit from specific guidance to support the HTA process?

- How to assess clinical effectiveness
- How to assess value for money (cost effectiveness)
- Decision making under high uncertainty
- Ensuring good stakeholder engagement
- Capturing wider issues in decision making (affordability, equity, innovation)

Should HTA agencies explore more pragmatic approaches for assessing COVID-19 technologies?

E.g., more open to non-RCT evidence, accepting of higher uncertainty, rapidly reviewing previous decisions.

- Yes
- No
- It depends... (please let us know why!)